For several decades, resins with protein A ligands have been the workhorse of monoclonal antibody (mAb) capture, as their application typically results in >95% purity. Protein A media effectively reduces most host cell protein (HCP) and DNA. However, it is increasingly recognized in the industry that resin-based chromatography matrices are associated with drawbacks, such as value-added pricing of protein A media due to limited supplier options, lower productivity (around 10-20 g/L.h in single column batch mode), which additionally leads to higher cost, ineffective lifetime utilization (particularly pre-commercial), and higher risk.
An alternative approach is to intensify this step by employing membrane-based Rapid Cycling Chromatography (RCC), which relies on an open pore matrix and convective mass transfer to reduce cycle times significantly. Innovative solutions such as RCC provide shorter return on investment times, less risk for bioburden events and significant shorter times to develop a process.
What Will You Learn:
- Membrane-based Rapid Cycling Chromatography (RCC) improves process economics
- The “one-batch, one-membrane approach” reduces risk and minimizes hands-on time
- Critical quality attributes and scalability are maintained, while flexibility is improved using Sartobind® Rapid A